MannKind’s future hinges on Tyvaso DPI's growth, R&D prospects, and financial stability despite competition and risks.

The company shows strong revenue growth, driven by Tyvaso (+33% YoY), and maintains high margins and low debt burden, with a 39% growth potential. Key growth drivers include Tyvaso's expansion ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10.

Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an ...

Dosage for transition from Tyvaso Inhalation Solution: see full labeling. Risk of symptomatic hypotension in those with low systemic arterial pressure. Hepatic insufficiency; titrate slowly.

At the moment, the only FDA-approved treatment for PH-ILD is United Therapeutics' Tyvaso inhaled prostacyclin analogue (treprostinil), which is delivered either using a nebuliser or as a DPI four ...

Earlier this month, the company announced that it had completed the full enrollment in the phase III TETON 1 study, which is evaluating the use of Tyvaso (treprostinil) inhalation solution ...

The company reported a 23% year-over-year revenue increase, reaching $748.9 million, largely driven by a 33% rise in Tyvaso sales, which totaled $433.8 million. Products like Orenitram and ...

United Therapeutics Corp (UTHR) reports a third consecutive year of record revenue, strategic clinical advancements, and significant shareholder returns.

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.